{"ticker": {"uuid": "ae5411df-3593-4a38-856b-8baefeb95722", "symbol": "RPRX", "name": "Royalty Pharma\u00a0Plc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "SEB Asset Management AB Invests $12.97 Million in Royalty Pharma PLC $RPRX", "summary": "", "url": "https://news.google.com/rss/articles/CBMizAFBVV95cUxNWkh4NzBKRFp0S3d1VG9ZUWYtQ0M0a3JSbWhqVG9DZWN2R2U2R0lrcnFzV1AwejZVb0diU1Z3d01EZC1GUmZnSUpOdnFKQjA0U0FSRGlVb2h3azlqQ05qV3poc25mSm1aLVIxYWpuTGZ0QUVJbU9ZUFdMbEhyblpjemxTNjVFM0ktSXF5aHJpNWJycnVxalRfTUdybmtuODU4NFJBcW9qeTdGTF9JQk5XNWJPYV9IelJTYXByNUQ2bThSZG9wampSR3EyaWQ?oc=5", "source_name": "MarketBeat", "published_at": "2026-07-21T09:45:52+00:00", "published_display": "21 Jul 2026 09:45", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "California Public Employees Retirement System Cuts Stake in Royalty Pharma PLC $RPRX", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3AFBVV95cUxNV0RCYXE2UXRYak1RVXhVcU1QMkpwYm9yOEdBc1hsQmRld3htSUp3eGV1emR1UGl5aEE5bHgwemdFZElqZ012M0FzODFPUXJGR29iVG4xVGlMb20xZE9BWUR2NzJUR2RwUENsTGUzRzJwV0tJNFliSTFxUDMzWU9BTTdPT1NldDlJTGljUUtrU0pOOUYzLVhRRkhjcjdtVG9tYTFraklLSjlTVjNwM0F1dVpMSUlPeTRHdVppTWVlWHA3enFJZ2E1LWs2X1NUd20zOFpLZGc0cVI3SkpQ?oc=5", "source_name": "MarketBeat", "published_at": "2026-07-21T08:06:07+00:00", "published_display": "21 Jul 2026 08:06", "sentiment": "negative", "sentiment_pct": 34, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Royalty Pharma PLC $RPRX Holdings Lowered by AlTi Global Inc.", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxQLWxtUkZOLXNnVk1ZbERMd1h6QzAtS2N2T2JndkFpX3NLQ2Y3NV9pbFpGRG5FbC1tN1I5eWx2NERmb3JaZVNpX1lScGdXVXhDeU9UTlh6aUVib3RIVEI0cGtkZDBQWFBoRTZmaC1wWUZocDFjY19UTXB2cDdIelU5UkN5cEVrcm5zTmFJemI1enR4VkFZU2VsSjAyMzV4Y0pkLUpucVVkdURHdTJXMmZ0bmh2bGRVeWFmY1JFOA?oc=5", "source_name": "MarketBeat", "published_at": "2026-07-21T07:27:39+00:00", "published_display": "21 Jul 2026 07:27", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Hsbc Holdings PLC Acquires 1,486,020 Shares of Royalty Pharma PLC $RPRX", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxNWHh5ODMxVTRuZU1DX25Ucld1MlVZSXpPR0Z5Sk1QVGVTRmxxM3ZwM1VTZjFoeXJpNWhQVnhpUzNwbHJTMXJJVVJwaEZVaFpmbWYtdS1wUUM0VFRYT3hfNjhFSGJ1SFRZN2U5VHdSYXR5Zm5CRDI4LUNZZ3loRHhlR1NUTFZWOGktdFoxMUZoQVNvRTlRQ1p1WEp2a0VpQjd1UkdyQmxPNnd6d1NBSFozZHpXTWtpT2dZbFdmNk5MZnJGcjB4RTZ1Vw?oc=5", "source_name": "MarketBeat", "published_at": "2026-07-20T08:55:22+00:00", "published_display": "20 Jul 2026 08:55", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Royalty Pharma declares third quarter 2026 dividend", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/royalty-pharma-declares-third-quarter-201500733.html", "source_name": "GlobeNewswire", "published_at": "2026-07-17T20:15:00+00:00", "published_display": "17 Jul 2026 20:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Royalty Pharma Announces Third Quarter 2026 Dividend of $0.235 per Class A Ordinary Share", "summary": "Royalty Pharma plc has declared a third-quarter 2026 dividend of $0.235 per Class A ordinary share, payable on September 10, 2026, to shareholders of record by August 14, 2026. The company, established in 1996, is a major buyer of biopharmaceutical royalties and funds innovation ", "url": "https://www.quiverquant.com/news/Royalty+Pharma+Announces+Third+Quarter+2026+Dividend+of+%240.235+per+Class+A+Ordinary+Share", "source_name": "Quiver Quantitative", "published_at": "2026-07-17T20:21:00", "published_display": "17 Jul 2026 20:21", "sentiment": "positive", "sentiment_pct": 65, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Royalty Pharma dividend arrives Sept. 10 for Aug. 14 record-date holders", "summary": "Royalty Pharma (Nasdaq: RPRX) has declared a third-quarter 2026 dividend of $0.235 per Class A ordinary share. This dividend will be paid on September 10, 2026, to shareholders who are on record as of August 14, 2026. Royalty Pharma is known as the largest buyer of biopharmaceuti", "url": "https://www.stocktitan.net/news/RPRX/royalty-pharma-declares-third-quarter-2026-p8qtz10b2cni.html", "source_name": "Stock Titan", "published_at": "2026-07-17T20:10:10", "published_display": "17 Jul 2026 20:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Royalty Pharma (NASDAQ:RPRX) Sets New 12-Month High - Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxNczFQQmVxX0RPRndxaERCcDFMZFA1eTNXcTNSNE4wV2dLTE14RDFraDdCVFZhYnJNemVTLUZPZ0VMYld0ZGJXVXdZOC1wMk80UmxhdmhfSzNraFJVQ21xZl9oSHF6U0JJeV9EWlF2MGdkaTA3MVAzNUhfRHJqS2VoQ203NmF6T21FRUhYVGM1dmxvcWtVWWtGRERhbHF6N3Q2RFo5eFJuLWNWUjhoS2EwUzN3?oc=5", "source_name": "MarketBeat", "published_at": "2026-07-17T14:45:29+00:00", "published_display": "17 Jul 2026 14:45", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Royalty Pharma PLC $RPRX Shares Sold by C WorldWide Group Holding A S", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxOZUFhSnZaV3g2c3BnOUpzbWFmVDAzd2E4bWIwMHlub1BnOFV1TGMybElBZkdYQ00xR0cwVy1XTFRLWXgyS0VOT0hsdklmd1BXQk9ScUNrdW01aWFmVFNaOEtmdHh6ODJidGsyX3lraDlaT21uUmUtLTlTYk5OWlZhbENjMnBFaXJ3NFR6R0YwZWF1MWhEeDl6dUNzLUUySEVVU3VwTG1DenhReXAyWG1TQVNiQlI0OVNGcXlncEhHbEV5cC1YUGNZOQ?oc=5", "source_name": "MarketBeat", "published_at": "2026-07-17T08:28:52+00:00", "published_display": "17 Jul 2026 08:28", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Royalty Pharma to announce second quarter 2026 financial results on August 5, 2026", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/royalty-pharma-announce-second-quarter-201500419.html", "source_name": "GlobeNewswire", "published_at": "2026-07-15T20:15:00+00:00", "published_display": "15 Jul 2026 20:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Royalty Pharma schedules 8 a.m. webcast for Aug. 5 results", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxPbW1qZTlma0hCNTVtNUZkM0RHZTdkRjJpU1ZCc1JIQlJMdS1yd1U3ZXdMSXdrLUFwN0FkakptdWtuU002b01pbTRsbE14d0t3YUUxMW5xYmVRZWtJSTFRaUlwNk1KdDZ3S3pid1puNF9IbWRRaWcxT0RveWhuT1IxR3ZvdGdtblp2TF8ySEFTazJUVTJQdjFjYzhCRWdPSS1obUFCVGUzY1hXZW05eTZ1ZnpRVkhqVVdVRFJlajVXUQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-15T20:15:00+00:00", "published_display": "15 Jul 2026 20:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Royalty Pharma (RPRX) Stock Analysis: A Strategic Look At Growth And Valuation Potential", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0gFBVV95cUxPWThaU2FFLWNjRlRjc0dYRGxrVVRCcjUzOFJxMFEyVmRnUi1xSDBGencwNnJuWUtCWkxwQUtOUlRjUzNJdlo1dE8wdWZYWXQxc3pPNFR1OWZxU3ZqQjZrMVZkWXhtYkY5eERUbXNpOFBjZnZMeVFVZmZBakZDNTRCQUtJQWV6cGZubzRUaEZ0ZjVGRjhjcjhMdnZMeWc4b1U0TG9nOFJYekg3a0dwamhueDluU1YtMlFnQ1A2R2tqRzBUa3g3UzNGNkpLd2dnbWpHcWc?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2026-07-13T09:22:42+00:00", "published_display": "13 Jul 2026 09:22", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Why Royalty Pharma (RPRX) Could Beat Earnings Estimates Again", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/why-royalty-pharma-rprx-could-161004361.html", "source_name": "Zacks", "published_at": "2026-07-10T16:10:04+00:00", "published_display": "10 Jul 2026 16:10", "sentiment": "positive", "sentiment_pct": 58, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Are You Looking for a Top Momentum Pick? Why Royalty Pharma (RPRX) is a Great Choice", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/looking-top-momentum-pick-why-160003487.html", "source_name": "Zacks", "published_at": "2026-07-10T16:00:03+00:00", "published_display": "10 Jul 2026 16:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Royalty Pharma PLC (RPRX) Hits Fresh High: Is There Still Room to Run?", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPY0VsaFZTT3htZi1MUUJNQTEtQnYxQXZTS1VJSzNZTXh6V2ZubjJZcGhybDE4ejlFd2ZCTDlFMVlnOTY0TGViaGEwNTNJRXlqMk5OcTNuYnpOT2VHd1FMaWhreTFCOTIwMDctcVcyeEVaY1pDeFRXSHNYaEFnel9LMm1IbmE3eVp4NGo5SUxKcTZBLTAwa1pSNQ?oc=5", "source_name": "Market source", "published_at": "2026-07-10T07:00:00+00:00", "published_display": "10 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Russell 1000 Defensive Inclusion Might Change The Case For Investing In Royalty Pharma (RPRX)", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-09T23:58:58+00:00", "published_display": "09 Jul 2026 23:58", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Royalty Pharma (RPRX) Could Be 2% Undervalued On Russell 1000 Defensive Index Addition", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-08T07:00:00+00:00", "published_display": "08 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ETFs Investing in Royalty Pharma Plc Class A Stocks", "summary": "This article lists various ETFs that include Royalty Pharma Plc Class A (RPD) stocks in their holdings. It provides detailed financial information for each ETF, such as market value, weight of RPD, issuer, management style, expense ratio, AUM, price, and 3-year NAV total return. ", "url": "https://www.tradingview.com/symbols/FWB-RPD/etfs/", "source_name": "TradingView", "published_at": "2026-07-04T09:41:24", "published_display": "04 Jul 2026 09:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] Royalty Pharma plc Insider Trading Activity", "summary": "Royalty Pharma plc EVP of Research & Investments Marshall Urist reported an open-market sale of 9,099 Class A Ordinary Shares on July 1, 2026, at a weighted average price of $55.8802 per share. This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan adopted o", "url": "https://www.stocktitan.net/sec-filings/RPRX/form-4-royalty-pharma-plc-insider-trading-activity-69940a3d4398.html", "source_name": "Stock Titan", "published_at": "2026-07-02T20:10:03", "published_display": "02 Jul 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Royalty Pharma (RPRX) EVP Hite sells 130,000 shares in 10b5-1 trades", "summary": "Royalty Pharma plc's EVP Christopher Hite sold 130,000 Class A Ordinary Shares on June 30, 2026, as part of a pre-arranged 10b5-1 trading plan. The shares were sold at weighted average prices between approximately $56 and $57. Hite now directly holds 40,000 shares, with an additi", "url": "https://www.stocktitan.net/sec-filings/RPRX/form-4-royalty-pharma-plc-insider-trading-activity-23e8097dc422.html", "source_name": "Stock Titan", "published_at": "2026-07-02T20:10:03", "published_display": "02 Jul 2026 20:10", "sentiment": "negative", "sentiment_pct": 28, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Royalty Pharma plc (RPRX) insider Marshall Urist reports sales totaling ~$1.95M", "summary": "Royalty Pharma plc insider Marshall Urist filed Form 144 notices for proposed sales of Common Stock, totaling approximately $1.95 million across three transactions in May and June 2026. The filing also disclosed an Equity Performance Award of 9,099 Class A Ordinary Shares granted", "url": "https://www.stocktitan.net/sec-filings/RPRX/144-royalty-pharma-plc-sec-filing-d2c0f255c237.html", "source_name": "Stock Titan", "published_at": "2026-07-01T20:40:38", "published_display": "01 Jul 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] Royalty Pharma plc SEC Filing", "summary": "This article reports a Form 144 SEC filing by Royalty Pharma plc (RPRX), indicating a proposed sale of 100,000 Class A Ordinary Shares with an aggregate market value of $5,709,000. These shares were acquired from the issuer in a private transaction on February 14, 2025. The filin", "url": "https://www.stocktitan.net/sec-filings/RPRX/144-royalty-pharma-plc-sec-filing-23f4ea9bf53b.html", "source_name": "Stock Titan", "published_at": "2026-07-01T19:41:40", "published_display": "01 Jul 2026 19:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Royalty Pharma (RPRX) director gets equity grant in lieu of cash", "summary": "Royalty Pharma (RPRX) director Bonnie L. Bassler received an equity grant of 689 Class A Ordinary Shares as compensation, valued at $37,500, in lieu of a quarterly cash retainer. The shares were issued under the company\u2019s 2020 Independent Director Equity Incentive Plan, with each", "url": "https://www.stocktitan.net/sec-filings/RPRX/form-4-royalty-pharma-plc-insider-trading-activity-07de742b15bb.html", "source_name": "Stock Titan", "published_at": "2026-07-01T05:10:43", "published_display": "01 Jul 2026 05:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Royalty Pharma, plc (RPRX) Rallied on Earnings Beat", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxQX0ZBdUJPWkJtRGxqUnVaa0FBekE5eXd0blhxWE1TYnY2Q09IaU82b1N5LTRBVGJQU0tpNE54OEs2bHA2MGw5TkdWVGJLc3MtR19XY3pyTFRYbWo5X2ROVWJkZERNc3J6VHAwZlNYUE5NVGMxY3ozSF8xZFV3S2lkcHppOGNwVW5uS0ZvVTk3QndwblNhaGtQejl0MDc?oc=5", "source_name": "Market source", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Royalty Pharma Plc Class A \u2013 SWB:RPD", "summary": "The article mentions the enterprise value to revenue forward for Royalty Pharma Plc Class A, traded on the Stuttgart Stock Exchange under the symbol RPD. It is a financial data point for the company in the Pharmaceuticals: Major industry within Health Technology. The content prov", "url": "https://www.tradingview.com/symbols/SWB-RPD/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T17:10:18", "published_display": "27 Jun 2026 17:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Royalty Pharma Plc Class A \u2013 SWB:RPD", "summary": "This article provides access to the \"Price to earnings forward\" financial metric for Royalty Pharma Plc Class A (SWB:RPD) on TradingView. It indicates that the market for this stock was closed with no trades at the time of access. The primary content focuses on directing users to", "url": "https://www.tradingview.com/symbols/SWB-RPD/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T06:39:14", "published_display": "27 Jun 2026 06:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Executive-linked fund sells 150K Royalty Pharma (RPRX) shares under 10b5-1 plan", "summary": "An entity linked to Christopher Hite, EVP and Chairman, Partnering at Royalty Pharma plc, sold 150,000 Class A Ordinary Shares in open-market transactions on June 23, 2026. These sales, executed at weighted average prices around $54, were pre-planned under a Rule 10b5-1 trading p", "url": "https://www.stocktitan.net/sec-filings/RPRX/form-4-royalty-pharma-plc-insider-trading-activity-366899c0504b.html", "source_name": "Stock Titan", "published_at": "2026-06-26T00:41:41", "published_display": "26 Jun 2026 00:41", "sentiment": "negative", "sentiment_pct": 41, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Royalty Pharma Plc For: 25 June By Investing.com", "summary": "This article provides details of a Form 4 filing for Royalty Pharma Plc on June 25, 2026. Form 4 filings typically report changes in beneficial ownership of securities by company insiders. The article also includes current market data for various indices, commodities, and currenc", "url": "https://za.investing.com/news/stock-market-news/form-4-royalty-pharmaplc-for-25-june-93CH-4344890", "source_name": "Investing.com South Africa", "published_at": "2026-06-25T23:20:00", "published_display": "25 Jun 2026 23:20", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Royalty Pharma Insider Sold Shares Worth $8,159,277, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/royalty-pharma-insider-sold-shares-211831438.html", "source_name": "MT Newswires", "published_at": "2026-06-25T21:18:31+00:00", "published_display": "25 Jun 2026 21:18", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Royalty Pharma Insider Sold Shares Worth $502,067, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/royalty-pharma-insider-sold-shares-211746217.html", "source_name": "MT Newswires", "published_at": "2026-06-25T21:17:46+00:00", "published_display": "25 Jun 2026 21:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Royalty Pharma (RPRX) EVP Marshall Urist sells 9,098 shares under 10b5-1 plan", "summary": "Royalty Pharma EVP Marshall Urist sold 9,098 Class A Ordinary Shares at a weighted average price of $55.1843 per share, totaling over $502,000, under a pre-arranged Rule 10b5-1 trading plan adopted on February 12, 2026. Following this transaction, Urist directly holds 9,099 share", "url": "https://www.stocktitan.net/sec-filings/RPRX/form-4-royalty-pharma-plc-insider-trading-activity-ad7697c1b194.html", "source_name": "Stock Titan", "published_at": "2026-06-25T21:41:41", "published_display": "25 Jun 2026 21:41", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Royalty Pharma Plc Class A Actuals & Estimates (NASDAQ:RPRX)", "summary": "This article provides an overview of Royalty Pharma plc (NASDAQ: RPRX) stock, including its current price, historical performance, and analyst forecasts. It also details the company's financial results, such as recent earnings per share and revenue, and key metrics like market ca", "url": "https://www.tradingview.com/symbols/NASDAQ-RPRX/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T18:09:51", "published_display": "25 Jun 2026 18:09", "sentiment": "positive", "sentiment_pct": 67, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 144 Royalty Pharma plc For: 24 June By Investing.com", "summary": "This article from Investing.com is a brief report about Royalty Pharma plc's Form 144 filing for June 24. It includes the ticker symbol RPRX which showed a slight increase of 0.76%. The content consists mostly of market data, indices, commodity prices, and other financial perform", "url": "https://au.investing.com/news/stock-market-news/form-144-royalty-pharma-plc-for-24-june-93CH-4503815", "source_name": "Investing.com Australia", "published_at": "2026-06-25T02:41:41", "published_display": "25 Jun 2026 02:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Marshall Urist sells shares at Royalty Pharma plc (NASDAQ: RPRX)", "summary": "Marshall Urist, an insider at Royalty Pharma plc (NASDAQ: RPRX), reported selling 13,684 shares on May 14, 2026, for $726,137.82 and another 13,684 shares on May 20, 2026, for $721,837.21. These transactions were disclosed in a Form 144 SEC filing, which also noted an Equity Perf", "url": "https://www.stocktitan.net/sec-filings/RPRX/144-royalty-pharma-plc-sec-filing-95c1604606f6.html", "source_name": "Stock Titan", "published_at": "2026-06-24T20:39:09", "published_display": "24 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Don't Ignore The Insider Selling In Royalty Pharma", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[SCHEDULE 13D/A] Royalty Pharma plc Amended Major Shareholder Report", "summary": "Butterfield Fiduciary Administrators Trust Company Limited and Achille G. Severgnini have filed Amendment No. 8 to their Schedule 13D for Royalty Pharma plc, indicating their beneficial ownership has decreased to 4.8% of outstanding Class A shares, below the 5% threshold. This fi", "url": "https://www.stocktitan.net/sec-filings/RPRX/schedule-13d-a-royalty-pharma-plc-amended-major-shareholder-report-e44e6cc5ea6d.html", "source_name": "Stock Titan", "published_at": "2026-06-16T20:09:34", "published_display": "16 Jun 2026 20:09", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Royalty Pharma (RPRX) director Carole Ho awarded 4,545 restricted shares", "summary": "Royalty Pharma plc director Carole Ho was awarded 4,545 Class A Ordinary Shares in the form of restricted stock units as compensation. The award, valued at $0.00 per share, is set to vest 100% on the earlier of one year from the grant date or the next annual shareholder meeting. ", "url": "https://www.stocktitan.net/sec-filings/RPRX/form-4-royalty-pharma-plc-insider-trading-activity-c185f7e8b06f.html", "source_name": "Stock Titan", "published_at": "2026-06-08T20:09:24", "published_display": "08 Jun 2026 20:09", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Royalty Pharma (RPRX) director awarded 4,545 restricted stock units in equity grant", "summary": "Royalty Pharma director Gregory Norden was awarded 4,545 Class A Ordinary Shares in restricted stock units (RSUs) on June 5, 2026, as an equity grant under the company\u2019s 2020 Independent Director Equity Incentive Plan. The RSUs have a grant price of $0.00 per share and are set to", "url": "https://www.stocktitan.net/sec-filings/RPRX/form-4-royalty-pharma-plc-insider-trading-activity-e851d0228fc3.html", "source_name": "Stock Titan", "published_at": "2026-06-08T20:09:24", "published_display": "08 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Royalty Pharma (RPRX) director receives 4,545 share unit award", "summary": "Royalty Pharma plc director Elizabeth H. Weatherman was granted an equity award of 4,545 restricted stock units, which are Class A Ordinary Shares. This compensation-related award, at no cash cost, will vest 100% on the earlier of one year from the grant date or the next annual s", "url": "https://www.stocktitan.net/sec-filings/RPRX/form-4-royalty-pharma-plc-insider-trading-activity-af4bc36c400e.html", "source_name": "Stock Titan", "published_at": "2026-06-08T20:09:24", "published_display": "08 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director Ted Love receives 4,545 RSUs at Royalty Pharma (RPRX)", "summary": "Royalty Pharma director Ted W. Love received an equity award of 4,545 Class A Ordinary Shares in the form of restricted stock units (RSUs). These RSUs, granted under the company's 2020 Independent Director Equity Incentive Plan, generally vest 100% on the earlier of one year from", "url": "https://www.stocktitan.net/sec-filings/RPRX/form-4-royalty-pharma-plc-insider-trading-activity-3233189086ef.html", "source_name": "Stock Titan", "published_at": "2026-06-08T20:09:24", "published_display": "08 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director at Royalty Pharma (RPRX) receives 4,545 restricted stock units grant", "summary": "Royalty Pharma plc director David C. Hodgson received a grant of 4,545 restricted stock units (RSUs) tied to Class A ordinary shares as equity compensation. These RSUs, awarded under the company's 2020 Independent Director Equity Incentive Plan, will vest 100% on the earlier of o", "url": "https://www.stocktitan.net/sec-filings/RPRX/form-4-royalty-pharma-plc-insider-trading-activity-885967431e77.html", "source_name": "Stock Titan", "published_at": "2026-06-08T20:09:24", "published_display": "08 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Royalty Pharma (RPRX) director awarded 4,545 RSUs under 2020 equity plan", "summary": "Royalty Pharma plc (RPRX) director Vlad Coric was granted 4,545 Restricted Stock Units (RSUs) at no cost under the company's 2020 Independent Director Equity Incentive Plan. These RSUs will vest 100% on the earlier of one year from the grant date or the next annual shareholder me", "url": "https://www.stocktitan.net/sec-filings/RPRX/form-4-royalty-pharma-plc-insider-trading-activity-3ab107d2e081.html", "source_name": "Stock Titan", "published_at": "2026-06-08T20:09:24", "published_display": "08 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Royalty Pharma (RPRX) awards 4,545 RSUs to board director", "summary": "Royalty Pharma (RPRX) reported that its director, Catherine M. Engelbert, received an award of 4,545 Class A Ordinary Shares in the form of restricted stock units (RSUs). This award was granted under the company\u2019s 2020 Independent Director Equity Incentive Plan at no cash cost to", "url": "https://www.stocktitan.net/sec-filings/RPRX/form-4-royalty-pharma-plc-insider-trading-activity-49c7edffd1f0.html", "source_name": "Stock Titan", "published_at": "2026-06-08T20:09:24", "published_display": "08 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Royalty Pharma (RPRX) director Bonnie Bassler awarded 4,545 RSUs, raising holdings to 78,492 shares", "summary": "Royalty Pharma (RPRX) director Bonnie L. Bassler was granted 4,545 restricted stock units (RSUs) as part of her compensation, increasing her direct holdings to 78,492 Class A Ordinary Shares. This award, made under the company's 2020 Independent Director Equity Incentive Plan, ve", "url": "https://www.stocktitan.net/sec-filings/RPRX/form-4-royalty-pharma-plc-insider-trading-activity-f0a62d3aacdf.html", "source_name": "Stock Titan", "published_at": "2026-06-08T20:09:24", "published_display": "08 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cash from operating activities of Royalty Pharma Plc Class A \u2013 XETR:RPD", "summary": "The article focuses on the \"Cash from operating activities\" for Royalty Pharma Plc Class A, traded on XETRA under the symbol RPD. It presents a data table showing the period, value, change, and percentage change for this financial metric. The content underscores the financial ove", "url": "https://www.tradingview.com/symbols/XETR-RPD/financials-cash-flow/cash-f-operating-activities/", "source_name": "TradingView", "published_at": "2026-06-06T23:10:10", "published_display": "06 Jun 2026 23:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Royalty Pharma (RPRX) shareholders back directors, pay and share issuance powers at 2026 AGM", "summary": "Royalty Pharma plc shareholders approved all proposals at its 2026 Annual General Meeting, with a strong quorum of 88.08% voting power. Key approvals included the election of all nine director nominees, executive compensation on a non-binding basis, and the ratification and re-ap", "url": "https://www.stocktitan.net/sec-filings/RPRX/8-k-royalty-pharma-plc-reports-material-event-d396febaa0cf.html", "source_name": "Stock Titan", "published_at": "2026-06-04T20:10:44", "published_display": "04 Jun 2026 20:10", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RPRX Stock Price, Quote & Chart | ROYALTY PHARMA PLC- CL A (NASDAQ:RPRX)", "summary": "This article provides a comprehensive overview of ROYALTY PHARMA PLC- CL A (NASDAQ:RPRX) stock, including its current price, performance metrics, and key statistics such as market cap, P/E ratio, and dividend yield. It also covers technical and fundamental analysis ratings from C", "url": "https://www.chartmill.com/stock/quote/RPRX/profile", "source_name": "ChartMill", "published_at": "2026-05-29T17:40:04", "published_display": "29 May 2026 17:40", "sentiment": "positive", "sentiment_pct": 75, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Royalty Pharma EVP & CFO Coyne sells $3.48 million in shares", "summary": "Terrance P. Coyne, EVP and CFO of Royalty Pharma plc, sold 64,399 Class A Ordinary Shares for approximately $3.48 million on May 26, 2026, executed via a pre-arranged 10b5-1 trading plan. This sale occurred near the stock's 52-week high, with the company showcasing strong Q1 2026", "url": "https://m.investing.com/news/insider-trading-news/royalty-pharma-evp--cfo-coyne-sells-348-million-in-shares-93CH-4715545?ampMode=1", "source_name": "Investing.com", "published_at": "2026-05-28T21:08:57", "published_display": "28 May 2026 21:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Investors May Respond To Royalty Pharma (RPRX) Strong Q1 Royalties And Expanding Biotech Partnerships", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-27T07:00:00+00:00", "published_display": "27 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Royalty Pharma (RPRX) Valuation Check After Strong Share Price Momentum And Royalty Growth Potential", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxNNC01SXRoN0QtYXpZMzAzZDQwVXZMV1E3T3FDM1FQcWtGOFB6SUVSbFNBUFVxaXpranZEanVNR1p0Y2pfTWxzSmxYQmo5THFyTkc2S3hLWU1LSmptdEFrRHN4MGhjTFVOdWx5d3lGYjhPRVdLcVdnbUJQakNRamtwMHRxWWpRclJWYnpXRDBUMWdvdmZ4OHkxNVFNbGhxbFVsM1E?oc=5", "source_name": "Market source", "published_at": "2026-05-25T07:00:00+00:00", "published_display": "25 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxQcjZqdzdBcURDdWxCZUtoU1dTaHYtVUFRdlo1a3ZGZGY3a1dBX2x2UVE3Y1hoX1duLXhGU2p0UXU2eTctNng5eFJ5c1M0bHBNQ0VmZTFZanhYU21yTVo0UTQtVENveVV1aWdpc3luUlgza3AyUEI2OGx4aEhXc0pBTHpWUThSYXI1S3RTS21lQ21vWjd6MGY4ZDRwVWlEakc3SmFKN09aM0Rlb2pFT3BNNW1GTExnSElFb2NqR3JhX0J3MlptQy1mMk9IOTZtdS1HU25fLU9aOU9XZi1PRDlkZVI2cnhackHSAewBQVVfeXFMTlc2N3pIUkxDd1NtTlVRMEdac1JNSDF3cUNidkZrTElQREZaUTZjZmFHdUVWYW8wcDg1LThGbnlPb0VQUFI4ZXdjSXR6Ym5DREM1X2lyQUtYTzF3XzBBTGRGcEZQQ3FjLWxCQ0locVM2dGZJR1kxYmlBQXdsbFhfbFFISS1wSUkxQmp4U2d2Z3JHbXRPMUpnajBydTRmNnQzZmF5eEdzOVFRNUdDNVV0aDJQNERCaXN3ZGo1UUc1ZGkwOFYzcDgxS1ltZllDeTFxNFIxT3FyOUxLMFNrLUhtOFNFV0xMYkM5TlpWMzk?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Income Investors Should Know That Royalty Pharma plc (NASDAQ:RPRX) Goes Ex-Dividend Soon", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxPbVprWjd2aWJjNkxOOUhUZmR6aU9wdjlRYl9Jbll6akFIbU9YTElLVzNwYVNiVlhhMGtVeV9vNl9JREJBSHZYZmY0OVNScXpZWUcyNFhja1NnNE9yQ1hQTXUtYllBMms0YzJIQWROemdqQWRTVkY5NnNRSVRnQmRFajJ0bVlsWnF1R0hYeGIzM1J1Y0lBNFVnM1FKT1JWcU9ZSU1z?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "10% Of This Royalty Pharma Insider's Holdings Were Sold", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxNTi1nVmtGck9HdTY1bFAyakV3SlV3LWhtWHRRTTNUQXpJQmpUZmFOcUxWSjloYTNaUWRYNUExSUx3YnNtNzIxa3RfRnNkMHhsektLYlNzUXNzMU5EZkNtNTFpZUs0X25WRXNuQ3lCUmZwNTIyUnk3U2RtemZ5enJiRW12bmFwTDV2eFZqOUczT3hDanNfalhWN3RWbDNlZ3JtTWc?oc=5", "source_name": "Market source", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Royalty Pharma (RPRX) Margin Drop To 33.9% Tests Bullish Growth Narrative In Q1 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4AFBVV95cUxOTmx1TTk0YWJwNjVaLUZ0QmJBYUNWU3N0T3gxZ0xCMGRhMGJ5c3c0OEw4U19pNHJsUkxSU05xaXZ4NGJJOGh6eThPN0pxWXFVVFR4SjBpbkdPMWpiUzVfLWVIdGQ4NWowWEZmNHBjMDduUW1UZFpPeUdXUWY3UVhjclhJcGs5M0g4TGFkTGRxZktyaUE2SVY5bXdIbDVsNHYyT09PUTUxbDZKT0llZ0ZsWW9PWUVBTlN2d2k2WUhrS2JETi1ZYll1dGprd3R0YnFxQ2lVbjc3MTIwYkppS256atIB5gFBVV95cUxQV2c4ME5LX1huVFJhUHBrUlotYzJLU3k1QlEyRlJidDQ4RENOZTVkbHNaRHFGTVJxaWNOZC01TFhxOXFBcEJyTWFWNlpldy0tb3B0NGJPSnc2anRGSnhXZEVDaGwzcHRmU19HWnpuTmpkLWtJc2Z3cGVxbXNVS3RRb1VINmtMUFZVZmlUd195TXo1UG9EUmZEd253bFNTUTltWXg5SHJhSkZycDFtYjdJV0FPYlF2RTAydmRDNnZhN2Nkay16eTEyLXItZ1dYR0hpVWQ2T0VobjU5ZXBJU2FIRHpINzBpUQ?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At Royalty Pharma (RPRX) Valuation After Its Recent Share Price Momentum", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxOSFBOa1h0RkVDcVJPcHdMQUZONVl5T0NWODItcjhzRmFiaTlORXZxazNBaHRXSmFoODBOcXkwU1d3cElkZk05bTZIRTBfc3AtVDk2aW9aaGxvdGJlektBektsTDdFQWtZaFlzcmtfUzQ4MEZBTnZtT3VnRE5ZVi1UZ3B0UmVRb1ZmV2dkdUFCQmFya1VmS250RHdkcFZrVnUy?oc=5", "source_name": "Market source", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "SEB Asset Management AB Invests $12.97 Million in Royalty Pharma PLC $RPRX", "summary": "", "url": "https://news.google.com/rss/articles/CBMizAFBVV95cUxNWkh4NzBKRFp0S3d1VG9ZUWYtQ0M0a3JSbWhqVG9DZWN2R2U2R0lrcnFzV1AwejZVb0diU1Z3d01EZC1GUmZnSUpOdnFKQjA0U0FSRGlVb2h3azlqQ05qV3poc25mSm1aLVIxYWpuTGZ0QUVJbU9ZUFdMbEhyblpjemxTNjVFM0ktSXF5aHJpNWJycnVxalRfTUdybmtuODU4NFJBcW9qeTdGTF9JQk5XNWJPYV9IelJTYXByNUQ2bThSZG9wampSR3EyaWQ?oc=5", "source_name": "MarketBeat", "published_at": "2026-07-21T09:45:52+00:00", "published_display": "21 Jul 2026 09:45", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "California Public Employees Retirement System Cuts Stake in Royalty Pharma PLC $RPRX", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3AFBVV95cUxNV0RCYXE2UXRYak1RVXhVcU1QMkpwYm9yOEdBc1hsQmRld3htSUp3eGV1emR1UGl5aEE5bHgwemdFZElqZ012M0FzODFPUXJGR29iVG4xVGlMb20xZE9BWUR2NzJUR2RwUENsTGUzRzJwV0tJNFliSTFxUDMzWU9BTTdPT1NldDlJTGljUUtrU0pOOUYzLVhRRkhjcjdtVG9tYTFraklLSjlTVjNwM0F1dVpMSUlPeTRHdVppTWVlWHA3enFJZ2E1LWs2X1NUd20zOFpLZGc0cVI3SkpQ?oc=5", "source_name": "MarketBeat", "published_at": "2026-07-21T08:06:07+00:00", "published_display": "21 Jul 2026 08:06", "sentiment": "negative", "sentiment_pct": 34, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Royalty Pharma PLC $RPRX Holdings Lowered by AlTi Global Inc.", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxQLWxtUkZOLXNnVk1ZbERMd1h6QzAtS2N2T2JndkFpX3NLQ2Y3NV9pbFpGRG5FbC1tN1I5eWx2NERmb3JaZVNpX1lScGdXVXhDeU9UTlh6aUVib3RIVEI0cGtkZDBQWFBoRTZmaC1wWUZocDFjY19UTXB2cDdIelU5UkN5cEVrcm5zTmFJemI1enR4VkFZU2VsSjAyMzV4Y0pkLUpucVVkdURHdTJXMmZ0bmh2bGRVeWFmY1JFOA?oc=5", "source_name": "MarketBeat", "published_at": "2026-07-21T07:27:39+00:00", "published_display": "21 Jul 2026 07:27", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Hsbc Holdings PLC Acquires 1,486,020 Shares of Royalty Pharma PLC $RPRX", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxNWHh5ODMxVTRuZU1DX25Ucld1MlVZSXpPR0Z5Sk1QVGVTRmxxM3ZwM1VTZjFoeXJpNWhQVnhpUzNwbHJTMXJJVVJwaEZVaFpmbWYtdS1wUUM0VFRYT3hfNjhFSGJ1SFRZN2U5VHdSYXR5Zm5CRDI4LUNZZ3loRHhlR1NUTFZWOGktdFoxMUZoQVNvRTlRQ1p1WEp2a0VpQjd1UkdyQmxPNnd6d1NBSFozZHpXTWtpT2dZbFdmNk5MZnJGcjB4RTZ1Vw?oc=5", "source_name": "MarketBeat", "published_at": "2026-07-20T08:55:22+00:00", "published_display": "20 Jul 2026 08:55", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Royalty Pharma declares third quarter 2026 dividend", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/royalty-pharma-declares-third-quarter-201500733.html", "source_name": "GlobeNewswire", "published_at": "2026-07-17T20:15:00+00:00", "published_display": "17 Jul 2026 20:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Royalty Pharma Announces Third Quarter 2026 Dividend of $0.235 per Class A Ordinary Share", "summary": "Royalty Pharma plc has declared a third-quarter 2026 dividend of $0.235 per Class A ordinary share, payable on September 10, 2026, to shareholders of record by August 14, 2026. The company, established in 1996, is a major buyer of biopharmaceutical royalties and funds innovation ", "url": "https://www.quiverquant.com/news/Royalty+Pharma+Announces+Third+Quarter+2026+Dividend+of+%240.235+per+Class+A+Ordinary+Share", "source_name": "Quiver Quantitative", "published_at": "2026-07-17T20:21:00", "published_display": "17 Jul 2026 20:21", "sentiment": "positive", "sentiment_pct": 65, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Royalty Pharma dividend arrives Sept. 10 for Aug. 14 record-date holders", "summary": "Royalty Pharma (Nasdaq: RPRX) has declared a third-quarter 2026 dividend of $0.235 per Class A ordinary share. This dividend will be paid on September 10, 2026, to shareholders who are on record as of August 14, 2026. Royalty Pharma is known as the largest buyer of biopharmaceuti", "url": "https://www.stocktitan.net/news/RPRX/royalty-pharma-declares-third-quarter-2026-p8qtz10b2cni.html", "source_name": "Stock Titan", "published_at": "2026-07-17T20:10:10", "published_display": "17 Jul 2026 20:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Royalty Pharma (NASDAQ:RPRX) Sets New 12-Month High - Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxNczFQQmVxX0RPRndxaERCcDFMZFA1eTNXcTNSNE4wV2dLTE14RDFraDdCVFZhYnJNemVTLUZPZ0VMYld0ZGJXVXdZOC1wMk80UmxhdmhfSzNraFJVQ21xZl9oSHF6U0JJeV9EWlF2MGdkaTA3MVAzNUhfRHJqS2VoQ203NmF6T21FRUhYVGM1dmxvcWtVWWtGRERhbHF6N3Q2RFo5eFJuLWNWUjhoS2EwUzN3?oc=5", "source_name": "MarketBeat", "published_at": "2026-07-17T14:45:29+00:00", "published_display": "17 Jul 2026 14:45", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Royalty Pharma PLC $RPRX Shares Sold by C WorldWide Group Holding A S", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxOZUFhSnZaV3g2c3BnOUpzbWFmVDAzd2E4bWIwMHlub1BnOFV1TGMybElBZkdYQ00xR0cwVy1XTFRLWXgyS0VOT0hsdklmd1BXQk9ScUNrdW01aWFmVFNaOEtmdHh6ODJidGsyX3lraDlaT21uUmUtLTlTYk5OWlZhbENjMnBFaXJ3NFR6R0YwZWF1MWhEeDl6dUNzLUUySEVVU3VwTG1DenhReXAyWG1TQVNiQlI0OVNGcXlncEhHbEV5cC1YUGNZOQ?oc=5", "source_name": "MarketBeat", "published_at": "2026-07-17T08:28:52+00:00", "published_display": "17 Jul 2026 08:28", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Royalty Pharma to announce second quarter 2026 financial results on August 5, 2026", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/royalty-pharma-announce-second-quarter-201500419.html", "source_name": "GlobeNewswire", "published_at": "2026-07-15T20:15:00+00:00", "published_display": "15 Jul 2026 20:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Royalty Pharma schedules 8 a.m. webcast for Aug. 5 results", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxPbW1qZTlma0hCNTVtNUZkM0RHZTdkRjJpU1ZCc1JIQlJMdS1yd1U3ZXdMSXdrLUFwN0FkakptdWtuU002b01pbTRsbE14d0t3YUUxMW5xYmVRZWtJSTFRaUlwNk1KdDZ3S3pid1puNF9IbWRRaWcxT0RveWhuT1IxR3ZvdGdtblp2TF8ySEFTazJUVTJQdjFjYzhCRWdPSS1obUFCVGUzY1hXZW05eTZ1ZnpRVkhqVVdVRFJlajVXUQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-15T20:15:00+00:00", "published_display": "15 Jul 2026 20:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Royalty Pharma (RPRX) Stock Analysis: A Strategic Look At Growth And Valuation Potential", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0gFBVV95cUxPWThaU2FFLWNjRlRjc0dYRGxrVVRCcjUzOFJxMFEyVmRnUi1xSDBGencwNnJuWUtCWkxwQUtOUlRjUzNJdlo1dE8wdWZYWXQxc3pPNFR1OWZxU3ZqQjZrMVZkWXhtYkY5eERUbXNpOFBjZnZMeVFVZmZBakZDNTRCQUtJQWV6cGZubzRUaEZ0ZjVGRjhjcjhMdnZMeWc4b1U0TG9nOFJYekg3a0dwamhueDluU1YtMlFnQ1A2R2tqRzBUa3g3UzNGNkpLd2dnbWpHcWc?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2026-07-13T09:22:42+00:00", "published_display": "13 Jul 2026 09:22", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Royalty Pharma (RPRX) Could Beat Earnings Estimates Again", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/why-royalty-pharma-rprx-could-161004361.html", "source_name": "Zacks", "published_at": "2026-07-10T16:10:04+00:00", "published_display": "10 Jul 2026 16:10", "sentiment": "positive", "sentiment_pct": 58, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Are You Looking for a Top Momentum Pick? Why Royalty Pharma (RPRX) is a Great Choice", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/looking-top-momentum-pick-why-160003487.html", "source_name": "Zacks", "published_at": "2026-07-10T16:00:03+00:00", "published_display": "10 Jul 2026 16:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Royalty Pharma PLC (RPRX) Hits Fresh High: Is There Still Room to Run?", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPY0VsaFZTT3htZi1MUUJNQTEtQnYxQXZTS1VJSzNZTXh6V2ZubjJZcGhybDE4ejlFd2ZCTDlFMVlnOTY0TGViaGEwNTNJRXlqMk5OcTNuYnpOT2VHd1FMaWhreTFCOTIwMDctcVcyeEVaY1pDeFRXSHNYaEFnel9LMm1IbmE3eVp4NGo5SUxKcTZBLTAwa1pSNQ?oc=5", "source_name": "Market source", "published_at": "2026-07-10T07:00:00+00:00", "published_display": "10 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Russell 1000 Defensive Inclusion Might Change The Case For Investing In Royalty Pharma (RPRX)", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-09T23:58:58+00:00", "published_display": "09 Jul 2026 23:58", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Royalty Pharma (RPRX) Could Be 2% Undervalued On Russell 1000 Defensive Index Addition", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-08T07:00:00+00:00", "published_display": "08 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ETFs Investing in Royalty Pharma Plc Class A Stocks", "summary": "This article lists various ETFs that include Royalty Pharma Plc Class A (RPD) stocks in their holdings. It provides detailed financial information for each ETF, such as market value, weight of RPD, issuer, management style, expense ratio, AUM, price, and 3-year NAV total return. ", "url": "https://www.tradingview.com/symbols/FWB-RPD/etfs/", "source_name": "TradingView", "published_at": "2026-07-04T09:41:24", "published_display": "04 Jul 2026 09:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] Royalty Pharma plc Insider Trading Activity", "summary": "Royalty Pharma plc EVP of Research & Investments Marshall Urist reported an open-market sale of 9,099 Class A Ordinary Shares on July 1, 2026, at a weighted average price of $55.8802 per share. This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan adopted o", "url": "https://www.stocktitan.net/sec-filings/RPRX/form-4-royalty-pharma-plc-insider-trading-activity-69940a3d4398.html", "source_name": "Stock Titan", "published_at": "2026-07-02T20:10:03", "published_display": "02 Jul 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Royalty Pharma (RPRX) EVP Hite sells 130,000 shares in 10b5-1 trades", "summary": "Royalty Pharma plc's EVP Christopher Hite sold 130,000 Class A Ordinary Shares on June 30, 2026, as part of a pre-arranged 10b5-1 trading plan. The shares were sold at weighted average prices between approximately $56 and $57. Hite now directly holds 40,000 shares, with an additi", "url": "https://www.stocktitan.net/sec-filings/RPRX/form-4-royalty-pharma-plc-insider-trading-activity-23e8097dc422.html", "source_name": "Stock Titan", "published_at": "2026-07-02T20:10:03", "published_display": "02 Jul 2026 20:10", "sentiment": "negative", "sentiment_pct": 28, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Royalty Pharma plc (RPRX) insider Marshall Urist reports sales totaling ~$1.95M", "summary": "Royalty Pharma plc insider Marshall Urist filed Form 144 notices for proposed sales of Common Stock, totaling approximately $1.95 million across three transactions in May and June 2026. The filing also disclosed an Equity Performance Award of 9,099 Class A Ordinary Shares granted", "url": "https://www.stocktitan.net/sec-filings/RPRX/144-royalty-pharma-plc-sec-filing-d2c0f255c237.html", "source_name": "Stock Titan", "published_at": "2026-07-01T20:40:38", "published_display": "01 Jul 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] Royalty Pharma plc SEC Filing", "summary": "This article reports a Form 144 SEC filing by Royalty Pharma plc (RPRX), indicating a proposed sale of 100,000 Class A Ordinary Shares with an aggregate market value of $5,709,000. These shares were acquired from the issuer in a private transaction on February 14, 2025. The filin", "url": "https://www.stocktitan.net/sec-filings/RPRX/144-royalty-pharma-plc-sec-filing-23f4ea9bf53b.html", "source_name": "Stock Titan", "published_at": "2026-07-01T19:41:40", "published_display": "01 Jul 2026 19:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Royalty Pharma (RPRX) director gets equity grant in lieu of cash", "summary": "Royalty Pharma (RPRX) director Bonnie L. Bassler received an equity grant of 689 Class A Ordinary Shares as compensation, valued at $37,500, in lieu of a quarterly cash retainer. The shares were issued under the company\u2019s 2020 Independent Director Equity Incentive Plan, with each", "url": "https://www.stocktitan.net/sec-filings/RPRX/form-4-royalty-pharma-plc-insider-trading-activity-07de742b15bb.html", "source_name": "Stock Titan", "published_at": "2026-07-01T05:10:43", "published_display": "01 Jul 2026 05:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Royalty Pharma, plc (RPRX) Rallied on Earnings Beat", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxQX0ZBdUJPWkJtRGxqUnVaa0FBekE5eXd0blhxWE1TYnY2Q09IaU82b1N5LTRBVGJQU0tpNE54OEs2bHA2MGw5TkdWVGJLc3MtR19XY3pyTFRYbWo5X2ROVWJkZERNc3J6VHAwZlNYUE5NVGMxY3ozSF8xZFV3S2lkcHppOGNwVW5uS0ZvVTk3QndwblNhaGtQejl0MDc?oc=5", "source_name": "Market source", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Royalty Pharma Plc Class A \u2013 SWB:RPD", "summary": "The article mentions the enterprise value to revenue forward for Royalty Pharma Plc Class A, traded on the Stuttgart Stock Exchange under the symbol RPD. It is a financial data point for the company in the Pharmaceuticals: Major industry within Health Technology. The content prov", "url": "https://www.tradingview.com/symbols/SWB-RPD/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T17:10:18", "published_display": "27 Jun 2026 17:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Royalty Pharma Plc Class A \u2013 SWB:RPD", "summary": "This article provides access to the \"Price to earnings forward\" financial metric for Royalty Pharma Plc Class A (SWB:RPD) on TradingView. It indicates that the market for this stock was closed with no trades at the time of access. The primary content focuses on directing users to", "url": "https://www.tradingview.com/symbols/SWB-RPD/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T06:39:14", "published_display": "27 Jun 2026 06:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Executive-linked fund sells 150K Royalty Pharma (RPRX) shares under 10b5-1 plan", "summary": "An entity linked to Christopher Hite, EVP and Chairman, Partnering at Royalty Pharma plc, sold 150,000 Class A Ordinary Shares in open-market transactions on June 23, 2026. These sales, executed at weighted average prices around $54, were pre-planned under a Rule 10b5-1 trading p", "url": "https://www.stocktitan.net/sec-filings/RPRX/form-4-royalty-pharma-plc-insider-trading-activity-366899c0504b.html", "source_name": "Stock Titan", "published_at": "2026-06-26T00:41:41", "published_display": "26 Jun 2026 00:41", "sentiment": "negative", "sentiment_pct": 41, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Royalty Pharma Plc For: 25 June By Investing.com", "summary": "This article provides details of a Form 4 filing for Royalty Pharma Plc on June 25, 2026. Form 4 filings typically report changes in beneficial ownership of securities by company insiders. The article also includes current market data for various indices, commodities, and currenc", "url": "https://za.investing.com/news/stock-market-news/form-4-royalty-pharmaplc-for-25-june-93CH-4344890", "source_name": "Investing.com South Africa", "published_at": "2026-06-25T23:20:00", "published_display": "25 Jun 2026 23:20", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Royalty Pharma Insider Sold Shares Worth $8,159,277, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/royalty-pharma-insider-sold-shares-211831438.html", "source_name": "MT Newswires", "published_at": "2026-06-25T21:18:31+00:00", "published_display": "25 Jun 2026 21:18", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Royalty Pharma Insider Sold Shares Worth $502,067, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/royalty-pharma-insider-sold-shares-211746217.html", "source_name": "MT Newswires", "published_at": "2026-06-25T21:17:46+00:00", "published_display": "25 Jun 2026 21:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Royalty Pharma (RPRX) EVP Marshall Urist sells 9,098 shares under 10b5-1 plan", "summary": "Royalty Pharma EVP Marshall Urist sold 9,098 Class A Ordinary Shares at a weighted average price of $55.1843 per share, totaling over $502,000, under a pre-arranged Rule 10b5-1 trading plan adopted on February 12, 2026. Following this transaction, Urist directly holds 9,099 share", "url": "https://www.stocktitan.net/sec-filings/RPRX/form-4-royalty-pharma-plc-insider-trading-activity-ad7697c1b194.html", "source_name": "Stock Titan", "published_at": "2026-06-25T21:41:41", "published_display": "25 Jun 2026 21:41", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Royalty Pharma Plc Class A Actuals & Estimates (NASDAQ:RPRX)", "summary": "This article provides an overview of Royalty Pharma plc (NASDAQ: RPRX) stock, including its current price, historical performance, and analyst forecasts. It also details the company's financial results, such as recent earnings per share and revenue, and key metrics like market ca", "url": "https://www.tradingview.com/symbols/NASDAQ-RPRX/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T18:09:51", "published_display": "25 Jun 2026 18:09", "sentiment": "positive", "sentiment_pct": 67, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 144 Royalty Pharma plc For: 24 June By Investing.com", "summary": "This article from Investing.com is a brief report about Royalty Pharma plc's Form 144 filing for June 24. It includes the ticker symbol RPRX which showed a slight increase of 0.76%. The content consists mostly of market data, indices, commodity prices, and other financial perform", "url": "https://au.investing.com/news/stock-market-news/form-144-royalty-pharma-plc-for-24-june-93CH-4503815", "source_name": "Investing.com Australia", "published_at": "2026-06-25T02:41:41", "published_display": "25 Jun 2026 02:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Marshall Urist sells shares at Royalty Pharma plc (NASDAQ: RPRX)", "summary": "Marshall Urist, an insider at Royalty Pharma plc (NASDAQ: RPRX), reported selling 13,684 shares on May 14, 2026, for $726,137.82 and another 13,684 shares on May 20, 2026, for $721,837.21. These transactions were disclosed in a Form 144 SEC filing, which also noted an Equity Perf", "url": "https://www.stocktitan.net/sec-filings/RPRX/144-royalty-pharma-plc-sec-filing-95c1604606f6.html", "source_name": "Stock Titan", "published_at": "2026-06-24T20:39:09", "published_display": "24 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Don't Ignore The Insider Selling In Royalty Pharma", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[SCHEDULE 13D/A] Royalty Pharma plc Amended Major Shareholder Report", "summary": "Butterfield Fiduciary Administrators Trust Company Limited and Achille G. Severgnini have filed Amendment No. 8 to their Schedule 13D for Royalty Pharma plc, indicating their beneficial ownership has decreased to 4.8% of outstanding Class A shares, below the 5% threshold. This fi", "url": "https://www.stocktitan.net/sec-filings/RPRX/schedule-13d-a-royalty-pharma-plc-amended-major-shareholder-report-e44e6cc5ea6d.html", "source_name": "Stock Titan", "published_at": "2026-06-16T20:09:34", "published_display": "16 Jun 2026 20:09", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Royalty Pharma (RPRX) director Carole Ho awarded 4,545 restricted shares", "summary": "Royalty Pharma plc director Carole Ho was awarded 4,545 Class A Ordinary Shares in the form of restricted stock units as compensation. The award, valued at $0.00 per share, is set to vest 100% on the earlier of one year from the grant date or the next annual shareholder meeting. ", "url": "https://www.stocktitan.net/sec-filings/RPRX/form-4-royalty-pharma-plc-insider-trading-activity-c185f7e8b06f.html", "source_name": "Stock Titan", "published_at": "2026-06-08T20:09:24", "published_display": "08 Jun 2026 20:09", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Royalty Pharma (RPRX) director awarded 4,545 restricted stock units in equity grant", "summary": "Royalty Pharma director Gregory Norden was awarded 4,545 Class A Ordinary Shares in restricted stock units (RSUs) on June 5, 2026, as an equity grant under the company\u2019s 2020 Independent Director Equity Incentive Plan. The RSUs have a grant price of $0.00 per share and are set to", "url": "https://www.stocktitan.net/sec-filings/RPRX/form-4-royalty-pharma-plc-insider-trading-activity-e851d0228fc3.html", "source_name": "Stock Titan", "published_at": "2026-06-08T20:09:24", "published_display": "08 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Royalty Pharma (RPRX) director receives 4,545 share unit award", "summary": "Royalty Pharma plc director Elizabeth H. Weatherman was granted an equity award of 4,545 restricted stock units, which are Class A Ordinary Shares. This compensation-related award, at no cash cost, will vest 100% on the earlier of one year from the grant date or the next annual s", "url": "https://www.stocktitan.net/sec-filings/RPRX/form-4-royalty-pharma-plc-insider-trading-activity-af4bc36c400e.html", "source_name": "Stock Titan", "published_at": "2026-06-08T20:09:24", "published_display": "08 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director Ted Love receives 4,545 RSUs at Royalty Pharma (RPRX)", "summary": "Royalty Pharma director Ted W. Love received an equity award of 4,545 Class A Ordinary Shares in the form of restricted stock units (RSUs). These RSUs, granted under the company's 2020 Independent Director Equity Incentive Plan, generally vest 100% on the earlier of one year from", "url": "https://www.stocktitan.net/sec-filings/RPRX/form-4-royalty-pharma-plc-insider-trading-activity-3233189086ef.html", "source_name": "Stock Titan", "published_at": "2026-06-08T20:09:24", "published_display": "08 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director at Royalty Pharma (RPRX) receives 4,545 restricted stock units grant", "summary": "Royalty Pharma plc director David C. Hodgson received a grant of 4,545 restricted stock units (RSUs) tied to Class A ordinary shares as equity compensation. These RSUs, awarded under the company's 2020 Independent Director Equity Incentive Plan, will vest 100% on the earlier of o", "url": "https://www.stocktitan.net/sec-filings/RPRX/form-4-royalty-pharma-plc-insider-trading-activity-885967431e77.html", "source_name": "Stock Titan", "published_at": "2026-06-08T20:09:24", "published_display": "08 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Royalty Pharma (RPRX) director awarded 4,545 RSUs under 2020 equity plan", "summary": "Royalty Pharma plc (RPRX) director Vlad Coric was granted 4,545 Restricted Stock Units (RSUs) at no cost under the company's 2020 Independent Director Equity Incentive Plan. These RSUs will vest 100% on the earlier of one year from the grant date or the next annual shareholder me", "url": "https://www.stocktitan.net/sec-filings/RPRX/form-4-royalty-pharma-plc-insider-trading-activity-3ab107d2e081.html", "source_name": "Stock Titan", "published_at": "2026-06-08T20:09:24", "published_display": "08 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Royalty Pharma (RPRX) awards 4,545 RSUs to board director", "summary": "Royalty Pharma (RPRX) reported that its director, Catherine M. Engelbert, received an award of 4,545 Class A Ordinary Shares in the form of restricted stock units (RSUs). This award was granted under the company\u2019s 2020 Independent Director Equity Incentive Plan at no cash cost to", "url": "https://www.stocktitan.net/sec-filings/RPRX/form-4-royalty-pharma-plc-insider-trading-activity-49c7edffd1f0.html", "source_name": "Stock Titan", "published_at": "2026-06-08T20:09:24", "published_display": "08 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Royalty Pharma (RPRX) director Bonnie Bassler awarded 4,545 RSUs, raising holdings to 78,492 shares", "summary": "Royalty Pharma (RPRX) director Bonnie L. Bassler was granted 4,545 restricted stock units (RSUs) as part of her compensation, increasing her direct holdings to 78,492 Class A Ordinary Shares. This award, made under the company's 2020 Independent Director Equity Incentive Plan, ve", "url": "https://www.stocktitan.net/sec-filings/RPRX/form-4-royalty-pharma-plc-insider-trading-activity-f0a62d3aacdf.html", "source_name": "Stock Titan", "published_at": "2026-06-08T20:09:24", "published_display": "08 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cash from operating activities of Royalty Pharma Plc Class A \u2013 XETR:RPD", "summary": "The article focuses on the \"Cash from operating activities\" for Royalty Pharma Plc Class A, traded on XETRA under the symbol RPD. It presents a data table showing the period, value, change, and percentage change for this financial metric. The content underscores the financial ove", "url": "https://www.tradingview.com/symbols/XETR-RPD/financials-cash-flow/cash-f-operating-activities/", "source_name": "TradingView", "published_at": "2026-06-06T23:10:10", "published_display": "06 Jun 2026 23:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Royalty Pharma (RPRX) shareholders back directors, pay and share issuance powers at 2026 AGM", "summary": "Royalty Pharma plc shareholders approved all proposals at its 2026 Annual General Meeting, with a strong quorum of 88.08% voting power. Key approvals included the election of all nine director nominees, executive compensation on a non-binding basis, and the ratification and re-ap", "url": "https://www.stocktitan.net/sec-filings/RPRX/8-k-royalty-pharma-plc-reports-material-event-d396febaa0cf.html", "source_name": "Stock Titan", "published_at": "2026-06-04T20:10:44", "published_display": "04 Jun 2026 20:10", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RPRX Stock Price, Quote & Chart | ROYALTY PHARMA PLC- CL A (NASDAQ:RPRX)", "summary": "This article provides a comprehensive overview of ROYALTY PHARMA PLC- CL A (NASDAQ:RPRX) stock, including its current price, performance metrics, and key statistics such as market cap, P/E ratio, and dividend yield. It also covers technical and fundamental analysis ratings from C", "url": "https://www.chartmill.com/stock/quote/RPRX/profile", "source_name": "ChartMill", "published_at": "2026-05-29T17:40:04", "published_display": "29 May 2026 17:40", "sentiment": "positive", "sentiment_pct": 75, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Royalty Pharma EVP & CFO Coyne sells $3.48 million in shares", "summary": "Terrance P. Coyne, EVP and CFO of Royalty Pharma plc, sold 64,399 Class A Ordinary Shares for approximately $3.48 million on May 26, 2026, executed via a pre-arranged 10b5-1 trading plan. This sale occurred near the stock's 52-week high, with the company showcasing strong Q1 2026", "url": "https://m.investing.com/news/insider-trading-news/royalty-pharma-evp--cfo-coyne-sells-348-million-in-shares-93CH-4715545?ampMode=1", "source_name": "Investing.com", "published_at": "2026-05-28T21:08:57", "published_display": "28 May 2026 21:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Investors May Respond To Royalty Pharma (RPRX) Strong Q1 Royalties And Expanding Biotech Partnerships", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-27T07:00:00+00:00", "published_display": "27 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Royalty Pharma (RPRX) Valuation Check After Strong Share Price Momentum And Royalty Growth Potential", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxNNC01SXRoN0QtYXpZMzAzZDQwVXZMV1E3T3FDM1FQcWtGOFB6SUVSbFNBUFVxaXpranZEanVNR1p0Y2pfTWxzSmxYQmo5THFyTkc2S3hLWU1LSmptdEFrRHN4MGhjTFVOdWx5d3lGYjhPRVdLcVdnbUJQakNRamtwMHRxWWpRclJWYnpXRDBUMWdvdmZ4OHkxNVFNbGhxbFVsM1E?oc=5", "source_name": "Market source", "published_at": "2026-05-25T07:00:00+00:00", "published_display": "25 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Income Investors Should Know That Royalty Pharma plc (NASDAQ:RPRX) Goes Ex-Dividend Soon", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxPbVprWjd2aWJjNkxOOUhUZmR6aU9wdjlRYl9Jbll6akFIbU9YTElLVzNwYVNiVlhhMGtVeV9vNl9JREJBSHZYZmY0OVNScXpZWUcyNFhja1NnNE9yQ1hQTXUtYllBMms0YzJIQWROemdqQWRTVkY5NnNRSVRnQmRFajJ0bVlsWnF1R0hYeGIzM1J1Y0lBNFVnM1FKT1JWcU9ZSU1z?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "10% Of This Royalty Pharma Insider's Holdings Were Sold", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxNTi1nVmtGck9HdTY1bFAyakV3SlV3LWhtWHRRTTNUQXpJQmpUZmFOcUxWSjloYTNaUWRYNUExSUx3YnNtNzIxa3RfRnNkMHhsektLYlNzUXNzMU5EZkNtNTFpZUs0X25WRXNuQ3lCUmZwNTIyUnk3U2RtemZ5enJiRW12bmFwTDV2eFZqOUczT3hDanNfalhWN3RWbDNlZ3JtTWc?oc=5", "source_name": "Market source", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Royalty Pharma (RPRX) Margin Drop To 33.9% Tests Bullish Growth Narrative In Q1 2026", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At Royalty Pharma (RPRX) Valuation After Its Recent Share Price Momentum", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxOSFBOa1h0RkVDcVJPcHdMQUZONVl5T0NWODItcjhzRmFiaTlORXZxazNBaHRXSmFoODBOcXkwU1d3cElkZk05bTZIRTBfc3AtVDk2aW9aaGxvdGJlektBektsTDdFQWtZaFlzcmtfUzQ4MEZBTnZtT3VnRE5ZVi1UZ3B0UmVRb1ZmV2dkdUFCQmFya1VmS250RHdkcFZrVnUy?oc=5", "source_name": "Market source", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 112, "total_relevant": 75, "sentiment_summary": {"positive": 16, "negative": 7, "neutral": 52, "score": 52, "total": 75, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 81, "events": [{"event": "general", "label": "Market update", "weight": 24.0, "count": 43}, {"event": "earnings", "label": "Earnings", "weight": 9.56, "count": 19}, {"event": "deals", "label": "Deals and strategy", "weight": 2.75, "count": 5}, {"event": "liquidity", "label": "Balance sheet", "weight": 2.2, "count": 4}, {"event": "capital_return", "label": "Capital return", "weight": 1.65, "count": 3}, {"event": "macro", "label": "Macro sensitivity", "weight": 0.55, "count": 1}], "positive_events": 16, "negative_events": 7}, "market_context": {"has_market_context": true, "latest_close": 58.18, "latest_week": "2026-07-17", "one_week_move": 3.1, "four_week_move": 9.9, "twelve_week_move": 18.3, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 0.950798, "market_dynamics_buy_signal": false, "relative_strength": 21.319976, "fair_value_gap": 75.7, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "positive", "expectation_probability": 61.9561, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+3.1% over one week, +9.9% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 61, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 20}, {"label": "Market source", "count": 10}, {"label": "simplywall.st", "count": 7}, {"label": "MarketBeat", "count": 6}, {"label": "TradingView", "count": 5}, {"label": "GlobeNewswire", "count": 2}, {"label": "Zacks", "count": 2}, {"label": "MT Newswires", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 66}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 43}, {"label": "Earnings", "count": 19}, {"label": "Deals and strategy", "count": 5}, {"label": "Balance sheet", "count": 4}, {"label": "Capital return", "count": 3}, {"label": "Macro sensitivity", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "52/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "81/100 classification confidence."}, {"label": "Company focus", "value": "66", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "2", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "+3.1% over one week, +9.9% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "SEB Asset Management AB Invests $12.97 Million in Royalty Pharma PLC $RPRX"}], "updated_at": "2026-07-22T06:36:54.913309+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}